Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. (Nasdaq: ZTEK, TSX-V: ZEN) is an intellectual property development and commercialization company focusing on next-generation healthcare solutions for prevention, detection, and treatment. Zentek is at the forefront of commercializing ZENGuard, a groundbreaking coating with 99% antimicrobial effectiveness, including activity against COVID-19. This technology has applications in a variety of fields, including surgical masks and HVAC systems.
The company operates a state-of-the-art production facility in Guelph, Ontario, and is ISO 13485:2016 certified. Zentek has developed a synergistic relationship with McMaster University to leverage an exclusive global license for their aptamer-based rapid pathogen detection technology. This partnership has led to promising results, including the C19HBA aptamer, which has shown therapeutic potential against SARS-CoV-2, outperforming leading monoclonal antibodies in preclinical trials.
Through its wholly-owned subsidiary Triera Biosciences Ltd., Zentek continues to advance its aptamer technology. Notably, their C19HBA aptamer has demonstrated robust preclinical efficacy in both prophylactic and therapeutic settings against various SARS-CoV-2 variants, including Omicron XBB 1.5. The company is now moving towards Phase 1 clinical trials and exploring further applications for their platform in infectious diseases and oncology.
In addition to healthcare, Zentek has made significant strides in the HVAC industry. The company's ZenGUARD™ Enhanced Air Filters aim to improve air quality without increasing energy consumption or emissions. Zentek's commitment to innovation is further evidenced by a series of partnerships and distribution agreements, including collaborations with Medwell Solutions LLC and DCL Supply Ltd. These partnerships aim to expand the market reach of Zentek's antimicrobial technologies.
Recent Achievements:
- Significant progress in preclinical trials for C19HBA aptamer as a therapeutic for SARS-CoV-2.
- A promising safety and toxicity profile for the C19HBA aptamer in preclinical tests.
- Exclusive distribution agreements for ZenGUARD™ Enhanced Surgical Masks in the U.S. with Medwell Solutions LLC and DCL Supply Ltd.
- Launch preparations for ZenGUARD™ Enhanced Air Filters in the HVAC market.
- Second patent for their GO-Ag+ nanocomposite as an antimicrobial agent, expanding its potential applications to both human and veterinary medicine.
Zentek continues to focus on commercializing its proprietary technologies, aiming to provide significant health benefits while also addressing environmental concerns. By offering innovative, safer, and greener products, Zentek seeks to give its commercial partners a competitive edge in their respective markets.
Zentek Ltd. (Nasdaq:ZTEK) has executed a property purchase agreement with its subsidiary, Albany Graphite Corp., to transfer the Albany Graphite Project. Albany will issue 59,999,900 common shares to Zentek in exchange for the ownership of the project, which includes mining claims and related assets. Albany plans to raise funds through a non-brokered private placement at $1.00 per subscription receipt, which will convert into common shares and warrants upon certain conditions being met. The funds will support community engagement, environmental studies, and an updated technical report. The Albany Graphite Project, located in Ontario, aims to supply a critical mineral for the Electric Vehicle industry, anticipating increased demand as projections suggest significant graphite production deficits in the coming decade.
Zentek Ltd. (NASDAQ: ZTEK, TSXV: ZEN) has announced the grant of 600,000 stock options to its directors, officers, and employees, exercisable at a price of $2.12 per share. The options will vest in stages over varying periods: one-third immediately, one-third after six months, and one-third after one year for executives, while others will vest one-third immediately, one-third after one year, and one-third after two years. This grant is part of the company’s annual compensation review. Zentek is a graphene technology company that develops products aimed at enhancing safety and performance, including the antimicrobial ZenGUARD™ coating, which has shown 99% efficacy against pathogens. The company’s production facility is in Guelph, Ontario. Further details can be found on their website and SEDAR profile.
Zentek Ltd. (NASDAQ:ZTEK) has filed patent applications for its antimicrobial technology, ZenGUARD, in 47 new jurisdictions, including the US and Europe. The patent examiner confirmed that ZenGUARD meets all requirements for patentability, including novelty and industrial applicability. This technology enhances the filtration efficiency of surgical masks and HVAC filters while exhibiting 99% antimicrobial activity. Zentek aims to commercialize ZenGUARD, asserting that it can provide significant competitive advantages to partners. The company also plans to pursue patents for additional technologies like ZenARMOR, focused on corrosion protection.
FAQ
What is the current stock price of Zentek (ZTEK)?
What is the market cap of Zentek (ZTEK)?
What is Zentek Ltd. specialized in?
What is ZENGuard?
What recent advancements has Zentek made in healthcare?
Who are Zentek's key partners?
What is Triera Biosciences Ltd.?
What is the latest news about Zentek?
Where is Zentek located?
What industries does Zentek serve?
What technology platforms does Zentek use?
How can I contact Zentek for more information?
